Atlas Trials

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Clinical trial NCT04100096 · COMPLETED

Trial details

NCT number
NCT04100096
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Borderline Personality Disorder
Start date
2019-10-17
Primary completion
2021-06-27
Enrollment
332

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.